Sweden-based Episurf Medical reached another milestone for the individualized Episealer knee resurfacing implant, as it plans the 800th surgery for the product. At the end of 2Q20, 327 patients had an Episealer implant for at least two years and 45 patients have surpassed five years. Per the company, revision rates remain low and clinical data showed significant improvements. Despite 1H20 Episurf revenues declining by 18% due to COVID, orders for Episealer increased by 21% for the period.
Episurf Medical CEO Pål Ryfors said, "We are looking forward to reaching out to a larger group of surgeons and make the Episealer® technology available for more patients as additional clinical evidence is available from this group of patients."